Oculis Holding Ag (OCS)

Apr 1, 2025, 4:00 AM EDT - 2 days ago

Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

Mar 20, 2025, 6:01 PM EDT - 14 days ago

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

Mar 14, 2025, 4:31 PM EDT - 20 days ago

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Mar 11, 2025, 4:30 PM EDT - 23 days ago

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

Mar 5, 2025, 4:00 AM EST - 4 weeks ago

Oculis to Present at Upcoming March Investor Conference

Feb 13, 2025, 7:40 PM EST - 6 weeks ago

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

Feb 7, 2025, 6:35 PM EST - 7 weeks ago

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

Jan 31, 2025, 4:00 PM EST - 2 months ago

Oculis updates share capital for its existing at-the-market offering program

Jan 21, 2025, 8:00 AM EST - 2 months ago

Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

Jan 6, 2025, 3:53 AM EST - 3 months ago

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

Nov 27, 2024, 4:15 AM EST - 4 months ago

Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities

Nov 13, 2024, 4:00 AM EST - 5 months ago

Oculis to Present at the Stifel 2024 Healthcare Conference

Nov 7, 2024, 4:00 AM EST - 5 months ago

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

Oct 21, 2024, 1:04 PM EDT - 5 months ago

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees

Oct 15, 2024, 4:00 AM EDT - 6 months ago

Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024

Oct 8, 2024, 5:00 AM EDT - 6 months ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

ENTO ONCO VRNA

Oct 2, 2024, 4:00 AM EDT - 6 months ago

Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

Sep 19, 2024, 1:00 PM EDT - 7 months ago

Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award

Aug 29, 2024, 4:00 AM EDT - 7 months ago

Oculis to Present at Upcoming September Investor Conferences

Aug 27, 2024, 4:00 PM EDT - 7 months ago

Oculis Publishes Consolidated Q2 Financial Statements and MD&A

Aug 27, 2024, 4:00 AM EDT - 7 months ago

Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update

Aug 27, 2024, 4:00 AM EDT - 7 months ago

Oculis Reports Q2 Financial Results and Provides Recent Company Update

Jul 30, 2024, 4:10 PM EDT - 8 months ago

Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Jun 27, 2024, 6:30 AM EDT - 10 months ago

Oculis and EURETINA Announces the Ramin Tadayoni Award

Jun 10, 2024, 5:00 AM EDT - 10 months ago

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

May 30, 2024, 4:00 AM EDT - 11 months ago

Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

May 8, 2024, 4:10 PM EDT - 11 months ago

Oculis Reports Q1 2024 Financial Results and Provides Company Updates

May 7, 2024, 4:05 PM EDT - 11 months ago

Oculis Publishes Invitation to the Annual General Meeting

May 6, 2024, 6:30 AM EDT - 11 months ago

Oculis to Present at Bank of America Global Healthcare Conference

Apr 22, 2024, 9:27 AM EDT - 1 year ago

Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market

Apr 11, 2024, 8:55 AM EDT - 1 year ago

Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market

Apr 10, 2024, 6:30 AM EDT - 1 year ago

Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development

Apr 8, 2024, 6:30 AM EDT - 1 year ago

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Oculis to Participate at Upcoming April Investor Conferences

Mar 18, 2024, 6:30 AM EDT - 1 year ago

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Feb 28, 2024, 6:30 AM EST - 1 year ago

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

Jan 29, 2024, 6:30 AM EST - 1 year ago

Oculis to Present at Upcoming February Investor Conferences

Jan 22, 2024, 6:30 AM EST - 1 year ago

Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024

Dec 20, 2023, 6:30 AM EST - 1 year ago

Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Dec 18, 2023, 6:30 AM EST - 1 year ago

Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema

Dec 7, 2023, 6:30 AM EST - 1 year ago

Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease

Nov 15, 2023, 6:30 AM EST - 1 year ago

Oculis Reports Q3 2023 Financial Results and Provides Company Update

Nov 8, 2023, 6:30 AM EST - 1 year ago

Oculis to Present at Upcoming November Investor Conferences

Nov 1, 2023, 6:30 AM EDT - 1 year ago

Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema

Oct 10, 2023, 6:30 AM EDT - 1 year ago

Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

Oct 5, 2023, 6:30 AM EDT - 1 year ago

Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema

Sep 11, 2023, 6:30 AM EDT - 1 year ago

Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase

Aug 29, 2023, 6:30 AM EDT - 1 year ago

Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update

Aug 17, 2023, 11:20 AM EDT - 1 year ago

Oculis: Swiss Pharma With Excellent Data, Unclear Fundamentals

Aug 8, 2023, 6:30 AM EDT - 1 year ago

OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery